## Connect to Cure®

## With its clinical-stage platform technology, Synaffix has established itself as the preferred technology provider enabling best-in-class targeted cancer therapeutics.

[About Synaffix](https://synaffix.com/about/company/)

![](https://synaffix.com/wp-content/uploads/2020/12/Synaffix-glycoconnect-ADC-glycanpocket.jpg)

## Connect to Innovate

Centered entirely around the antibody glycan, Synaffix has established a simple, rapidly deployable [technology platform](https://synaffix.com/platform/technology/), enabling any company with an antibody to develop a proprietary, [best-in-class ADC](https://synaffix.com/technology/?adcs) or [bispecific](https://synaffix.com/technology/?bispecifics).

[About the Platform](https://synaffix.com/platform/technology/)

## Connect to Partner

Under a focused technology out-licensing business model, Synaffix has delivered multiple best-in-class therapeutic candidates for our partners’ pipelines.

[Collaborate with Synaffix](https://synaffix.com/collaborate-with-us/)

**Next-Generation ADCs Being Developed under License Agreements**

##### Partner

##### Program   (Target)

##### Preclinical

##### Phase 1

##### Pivotal (Phase 2/3)

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/Innovent_Biologics_logo-e1627747717376.png)](https://www.innoventbio.com/)

###### IBI343   (Claudin 18.2)

###### Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/lepu.png)](https://en.lepubiopharma.com/)

###### MRG004A   (TF)

###### Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/image002.png)](https://macrogenics.com/)

###### MGC026   (B7-H3)

###### MGC028   (ADAM9)

###### 2x Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/download.png)](https://www.mersana.com/)

###### XMT-1660  (B7-H4)

##### Partner / Licensee

[![JNJ_Logo_Shorthand_Red_RGB](https://synaffix.com/wp-content/uploads/2020/10/JNJ_Logo_Shorthand_Red_RGB_EDIT.jpg)](https://www.jnj.com/)

in collaboration with Mersana Therapeutics, Inc.

###### Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/KIVU-Black-on-Clear.png)](https://kivubioscience.com/)

###### KIVU-107

###### KIVU-305

###### KIVU-202

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/ablbio-logo-e1694686639975.png)](https://www.ablbio.com/en/company/main)

###### 2x Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/img_ogp.png)](https://www.kyowakirin.com/)

###### 2x Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/CKD-logo.jpg)](https://www.ckdpharm.com/en/company/summary_ckd.do)

###### CKD-703   (c-MET)

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/elevation-oncology-logo.png)](https://elevationoncology.com/)

###### EO-1022   (HER3)

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/sotiologo-e1697476331738.png)](https://sotio.com/)

###### SOT-109

###### SOT-112

###### SOT-113

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/Hummingbird_Bioscience_Logo_Logo-e1672822603219.jpg)](https://hummingbirdbioscience.com/)

###### Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/amgen-cardiovascular-logo-vector-e1672930994994.png)](https://www.amgen.com/)

###### Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/114246.webp)](https://www.bighatbio.com/)

###### Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/image003-e1641566826911.png)](https://genmab.com/)

###### Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/Boehringer_Ingelheim_Logo.png)](https://www.boehringer-ingelheim.com/)

###### Undisclosed

##### Partner / Licensee

[![](https://synaffix.com/wp-content/uploads/2020/10/mtp-logo-stacked.webp)](https://www.mt-pharma.co.jp/e/)

###### Undisclosed

**Next-Generation ADCs Being Developed that Contain Synaffix Technology**

##### Organization

##### Program   (Target)

##### Preclinical

##### Phase 1

##### Pivotal (Phase 2/3)

##### Organization

#### National Cancer Institute\*

\*Sponsor of clinical trial of ADC containing Synaffix technology; this clinical trial is not subject to any license agreement between NCI and Synaffix

###### ADCT-701   (DLK-1)

### News

[Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology](https://synaffix.com/boehringer-ingelheim-broadens-oncology-portfolio-with-license-for-synaffixs-adc-technology/)

January 10, 2025

[Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology](https://synaffix.com/synaffix-and-mitsubishi-tanabe-pharma-sign-license-agreement-for-adc-technology/)

January 9, 2025

[Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion](https://synaffix.com/elevation-oncology-licenses-adc-technology-from-synaffix-to-drive-pipeline-expansion/)

December 12, 2024

[Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications](https://synaffix.com/synaffix-licenses-metal-free-click-chemistry-technology-to-illumina-for-next-generation-dna-sequencing-applications/)

December 6, 2024

[Read All News >>](https://synaffix.com/news/)

## Connect

[Contact Us](https://synaffix.com/contact/)

[Meet Us at Events](https://synaffix.com/events-media/)